Business Context and Reporting Period
This Form 8-K Current Report from cbdMD, Inc. covers events occurring on February 16, 2023, specifically the company's 2023 Annual Meeting of Shareholders, and subsequent board actions on February 17, 2023. The company is incorporated in North Carolina and trades on the NYSE American under the symbols YCBD and YCBD PR A.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q filings for financial performance details.
Material Changes and Shareholder Votes
At the annual meeting, 29,962,710.69 shares (49% of outstanding shares) were represented, constituting a quorum. All three proposals were approved:
- Proposal 1 (Director Elections): Four directors were elected to serve until the 2024 annual meeting: Bakari Sellers, William F. Raines, III, Scott G. Stephen, and Dr. Sibyl Swift. All received majority "For" votes.
- Proposal 2 (Auditor Ratification): Shareholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm.
- Proposal 3 (Reverse Stock Split Authorization): Shareholders approved an amendment to the Articles of Incorporation authorizing the Board to effect a reverse stock split at a ratio between 1-for-20 and 1-for-50 within one year of the meeting.
Management Commentary, Outlook, and Corporate Actions
Following the meeting on February 17, 2023, the Board of Directors announced significant leadership and committee changes:
- Executive Appointments: Scott Stephen was appointed Chairman of the Board; Kevin MacDermott was appointed President; T. Ronan Kennedy was appointed Chief Financial Officer, Chief Operating Officer, Secretary, and Treasurer.
- Committee Appointments:
- Audit Committee: William F. Raines, III (Chairman), Bakari Sellers, Scott G. Stephen.
- Compensation, Corporate Governance and Nominating Committee: Bakari Sellers (Chairman), William F. Raines, III, Scott G. Stephen.
- Compensation: Board fees remain consistent with the prior year, with an additional $22,500 annual fee for the independent Chairman.
The filing does not contain specific guidance, risk factors, or contingencies beyond the standard disclosures referenced in the proxy statement.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and implementation date, as the Board has discretion to determine the ratio between 1:20 and 1:50 within one year.
- Confirm the impact of the new executive leadership team (MacDermott and Kennedy) on the company's operational strategy.
- Review the definitive proxy statement (Schedule 14A filed January 4, 2023) for detailed background on the director nominees and the rationale for the reverse stock split.
- Check subsequent filings for the official announcement of the reverse stock split execution.